SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 4,665 Shares of Company Stock

SiBone logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • SiBone insider Anshul Maheshwari sold 4,665 shares at an average $23.32, totaling about $108,788. The sale covered tax withholding on vested equity awards; he retained 206,585 shares.
  • SiBone’s latest quarterly results beat analyst expectations, reporting a loss of $0.08 per share versus estimates of $0.13 and revenue of $55.7 million.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $25; seven analysts rated the stock Buy and one rated it Sell.
  • MarketBeat previews the top five stocks to own by December 1st.

SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 4,665 shares of the business's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $23.32, for a total transaction of $108,787.80. Following the sale, the insider owned 206,585 shares in the company, valued at $4,817,562.20. This trade represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

  • On Tuesday, November 17th, Anshul Maheshwari sold 1,715 shares of SiBone stock. The shares were sold at an average price of $23.19, for a total transaction of $39,770.85.
  • On Wednesday, November 4th, Anshul Maheshwari sold 3,247 shares of SiBone stock. The shares were sold at an average price of $25.00, for a total transaction of $81,175.00.
  • On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The stock was sold at an average price of $22.50, for a total value of $84,105.00.
  • On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The stock was sold at an average price of $19.50, for a total value of $33,754.50.
  • On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total value of $60,321.24.
  • On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total value of $233,999.96.
  • On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.

SiBone Price Performance

Shares of SIBN stock traded up $0.38 during mid-day trading on Wednesday, hitting $23.54. 1,120,107 shares of the stock traded hands, compared to its average volume of 644,914. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -75.93 and a beta of 0.64. The company's 50-day simple moving average is $20.56 and its 200-day simple moving average is $16.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.15 and a current ratio of 7.58.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The company had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. As a group, equities research analysts expect that SiBone will post -0.34 earnings per share for the current year.

Institutional Trading of SiBone

A number of hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC increased its position in shares of SiBone by 51.8% in the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company's stock worth $132,649,000 after acquiring an additional 2,774,795 shares in the last quarter. Granahan Investment Management LLC raised its holdings in shares of SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock valued at $21,965,000 after acquiring an additional 858,942 shares during the period. Paradigm Capital Management Inc. NY lifted its position in shares of SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company's stock valued at $14,228,000 after acquiring an additional 598,300 shares in the last quarter. Marshall Wace LLP lifted its position in shares of SiBone by 1.2% in the 3rd quarter. Marshall Wace LLP now owns 698,416 shares of the company's stock valued at $13,130,000 after acquiring an additional 8,128 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of SiBone by 41.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company's stock valued at $7,816,000 after acquiring an additional 182,465 shares in the last quarter. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on SIBN. Needham & Company LLC dropped their price target on shares of SiBone from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Tuesday, November 3rd. UBS Group lifted their price objective on shares of SiBone from $25.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, November 3rd. Citigroup reiterated a "market outperform" rating on shares of SiBone in a report on Tuesday, November 3rd. Truist Financial increased their target price on shares of SiBone from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, October 14th. Finally, Weiss Ratings upgraded shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 20th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $25.00.

Read Our Latest Stock Analysis on SiBone

About SiBone

(Get Free Report)

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.

Further Reading

Insider Buying and Selling by Quarter for SiBone (NASDAQ:SIBN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SiBone Right Now?

Before you consider SiBone, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.

While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines